Back to results
US 12,703,751 B2Granted
Caninized rat antibodies to canine interleukin-31 receptor alpha
AssigneeIntervet Inc.
InventorsMohamad Morsey, Yuanzheng Zhang, Anasuya Saha
Life of this patent
Estimating the term…
Abstract
The present invention provides caninized rat antibodies to canine IL-31 receptor alpha that have a high binding affinity for canine IL-31 receptor alpha, and that can block the binding of canine IL-31 to canine IL-31 receptor alpha. The present invention further provides the use of the antibodies for the treatment of atopic dermatitis in dogs.
Claims13
An isolated mammalian antibody or antigen binding fragment thereof that binds canine interleukin-31 receptor alpha (canine IL-31RA) comprising a set of six complementary determining regions (CDRs), three of said six CDRs are heavy chain CDRs (HCDRs):
- CDR heavy 1 (HCDR1), CDR heavy 2 (HCDR2), and CDR heavy 3 (HCDR3), and three of said six CDRs are light chain CDRs (LCDRs):
- CDR light 1 (LCDR1), CDR light 2 (LCDR2), and CDR light 3 (LCDR3);
- and
- wherein the set of six CDRs are selected from the group of sets consisting of (a)-(f);
- wherein for set (a):
- HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 31;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 32;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 33;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 34;
- LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 35;
- and
- LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 36;
- wherein for set (b):
- HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 31;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 32;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 33;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 34;
- LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 37;
- and
- LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 36;
- wherein for set (c):
- HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 31;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 32;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 33;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 38;
- LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 35;
- and
- LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 36;
- wherein for set (d):
- HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 31;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 32;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 43;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 44;
- LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 35;
- and
- LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 45;
- wherein for set (e):
- HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 31;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 32;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 39;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 40;
- LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 35;
- and
- LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 36;
- and
- wherein for set (f):
- HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 31;
- HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 41;
- HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 39;
- LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 42;
- LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 35;
- and
- LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 36.
86 more elements
Dependencies are inferred from the claim text.